Impact of pelvic lymphadenectomy during primary cytoreductive surgery on survival in epithelial ovarian cancer: A prospective study.

Abstract

Listen

Translate article

e15563 Background: To evaluate the impact of pelvic lymphadenectomy during primary cytoreductive surgery on survival in epithelial ovarian cancer (EOC). Methods: Between October 2008 and July 2010, 26 patients of EOC, FIGO stage IC-IV underwent primary cytoreductive surgery followed by six cycles of chemotherapy with paclitaxel and carboplatin. 13 patients (study group) underwent pelvic lymphadenectomy and 13 patients (control group) did not. Results: Patient characteristics were similar in both groups with respect to median age (49 yrs vs 50 yrs, p=0.3), menopausal status (53.8% vs 69.2%, p=0.4), mean Hb [G/dl] (10.7 vs 10.8, p=0.8) and mean albumin (G/dl; 3.7 vs 3.7, p= 0.9). However patients in control group had more advanced disease, FIGO stage III-IV, 84.6% vs 38.5%, p=0.04. Intraoperative data was not significantly different in study vs control groups; operating time (126 mins vs 132 mins, p=0.2), mean blood loss (815.4 mL vs 1,000mL, p=0.06), mean blood transfusion (1,300 mL vs 1,800 mL, p=0.09). Postoperative complications included sepsis (7.6% vs 23.07%, p=0.5), vesico-vaginal fistula (7.6% vs 0%, p=1.0), subacute intestinal obstruction (0% vs 7.6%, p=1.0), haemorrhage (0% vs 15.3 %, p=0.4), admissions in ICU (7.6% vs 23.07%, p=0.5),seizures (7.6% vs 0%, p=1.0), urinary tract infection (15.3% vs 7.6%; p=1.0) in study and control groups respectively. Postoperatively, 3 patients died in control group compared to one in study group (7.6% vs 23.07%, p=0.5). Optimal debulking rate (residual disease ≤ 1 cm) was higher in the study group; 84.6% vs 23.08%, p=0.005. The median progression free survival is 13 months (range 7.8 to 24.1 months) vs 12.1 months (range 6.1 to 26.7 months ) and the median overall survival is 13.3 months (range 8.2 to 28.6 months) vs 16.1 months (range 7.2 to 28.6 months) in the study and control group respectively. Conclusions: In this pilot study, we did not observe significant difference between progression free survival and overall survival in patients who underwent lymphadenectomy compared to control group.